Carregant...
HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer
Tamoxifen is a commonly used drug to treat estrogen receptor-positive patients with breast cancer. Despite the outstanding efficacy of tamoxifen, approximately one-third of patients develop resistance toward it, thereby presenting a therapeutic challenge. HOX genes may be involved in the acquisition...
Guardat en:
| Publicat a: | J Cancer |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Ivyspring International Publisher
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8210559/ https://ncbi.nlm.nih.gov/pubmed/34149926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.59740 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|